Radiation plus targeted pill vs pill alone for EGFR/ALK-NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have non-small cell lung cancer (NSCLC) confirmed by biopsy or pathology report
- Have a tumor mutation in EGFR or ALK/ROS (not negative for these)
- Have been on a targeted TKI pill for about 2–4 months and your cancer has not progressed
- Have limited spread: 1–5 metastatic sites away from the main tumor and nearby lymph nodes
- Be able to safely receive focused radiation to the involved areas and continue the TKI pill
- Have certain blood counts from within 15 days: neutrophils ≥500, platelets ≥50,000, and hemoglobin ≥8.0 (transfusion allowed to reach the number)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This trial tests if giving radiation to the main lung tumor before starting a targeted therapy pill can help delay the cancer from growing. It is for people with advanced non-small cell lung cancer that has a specific genetic change and who have not had targeted therapy before.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.